- Cost for cGMP allogeneic MSCs at <$50 per million cells for final drug product at USD 3K-20k (depending on body mass and dose regime).
- Drug Product for cGMP autologous MSCs at $30,000 per patient.
Highest Yield. Affordable Cost. Linearly scalable. Quality by design. These are our COGS targets at production scale which takes into account commercial batch sizes based on optimized conditions and done by Esco Aster in Singapore which includes our current prevailing rate of proprietary cell lines, media, other ancilliary consumables, and labour. These costs may be subject to market changes based on the prevailing rate.
Costs may vary if done by external party based on their labour rate, local conditions and own cell line, media, and consumables.
Drug product costing is ex-factory Singapore not inclusive of cold chain, transport logistics, tax, other local costs from regulatory, local agents, marketing, further processing (e.g. controlled rate of thawing, reconstitution, secondary packaging etc.), and other costs which are not stated here but part of final product costing)
Contact us to perform a cost analysis based on your specific requirements!
(Autologous CAR-T / CAR-Immune)
(Allogeneic CAR-T / CAR-Immune )
We solve adherent scale-up problems and provides a single-use bioprocessing method with closed, automated cell harvesting from seed preparation (0.1 L packed bed volume) to production scale (5,000 L packed-bed volume - bioequivalence of 50,000 L in suspension) all in the same 3D Tide Motion®.
We provide fermentation capabilities from Diagnostic Antigen / Antibodies, Peptides, Intermediates (Viral Vectors), Therapeutics, to Food Ingredients / Products for Cellular Agriculture / Alternative Proteins in both continuous liquid and solid-state fermentation.
We have focused on API chemical process development using continuous flow processes. We have the expertise, local collaborations and state-of-the-art facilities to address your process requirements pertaining to Active Pharmaceutical Ingredient (API) synthesis or multistep synthesis of functional organic molecules.
We are now expanding our territories in providing the pharmaceutical industry with new technologies based on the most innovative way of granulating, drying and making tablets using potent APIs for our clients.
We have the expertise and experience in providing clients process development and scale-up manufacturing of their food ingredients and food products. We utilize linearly scalable and cost-efficient bioprocessing technology for cellular agriculture/alternative protein products.
Extracellular vesicles or EVs have emerged as a new class of nanovehicles, comprising of nanovesicles such as exosomes (30 – 200 nm), microvesicles (MVs) (50 nm – 1um), and apoptic bodies (500 – 1000 nm). EVs have a remarkable potential as novel candidates for their efficiency as a vehicle to deliver therapeutics/drugs as cargo to a disease site and are key for intercellular communication.